Lexicon Pharma (LXRX) Tops Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.48 +1.37%
Revenue Growth %: -79.9%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
COHR, ATS, SICP, More
Revenue Growth %: -79.9%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of $0.01, $0.10 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $28.86 million versus the consensus estimate of $6.49 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phibro Animal Health (PAHC) Tops Q1 EPS by 2c; Offers Guidance
- Brookfield Renewable Energy Partners (BEP) Misses Q3 EPS by 15c
- Palomar Holdings Inc. (PLMR) Tops Q3 EPS by 46c; offers outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
